Clinical Trials Sponsored by NovoCure GmbH

Total 3354 results

NovoCure GmbH

Active, not recruiting

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

NSCLC | Nonsmall Cell Lung Cancer

United States, Poland, Hong Kong, China, Spain, Serbia, Croatia, France, Canada, Netherlands, Austria, Belgium, Bulgaria, Czechia, Germany, Hungary, Italy, Switzerland
NovoCure GmbH

Active, not recruiting

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Brain Metastases From Non-small Cell Lung Cancer (NSCLC)

United States, China, Israel, Spain, Austria, Canada, Hong Kong, Germany, France, Bulgaria, Croatia, Hungary, Italy, Poland, Serbia
NovoCure GmbH

Unknown

Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)

Hepatocellular Carcinoma

Italy, Czechia, France, Germany, Poland, Spain
NovoCure GmbH

Recruiting

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

Spain
NovoCure GmbH

Recruiting

TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study (TIGER Meso)

Pleural Mesothelioma

Germany, Italy, Netherlands
NovoCure GmbH

Completed

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge

COVID-19

Israel
NovoCure GmbH

Not yet recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (LUNAR-2)

Metastatic Non-small Cell Lung Cancer
NovoCure GmbH

Active, not recruiting

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (EF-32)

Glioblastoma Multiforme

United States, United Kingdom, Israel, Germany, Japan, Canada, France, Switzerland, Belgium, Czechia, Austria
NovoCure GmbH
Merck Sharp & Dohme LLC

Recruiting

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

Non-small Cell Lung Cancer

United States
NovoCure GmbH
Zai Lab (Shanghai) Co., Ltd.

Unknown

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Gastric Cancer | GastroEsophageal Cancer

Hong Kong
Prof. Franciszek Lukaszczyk Memorial Oncology Center
NovoCure GmbH

Active, not recruiting

TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine (TaRRGET)

Glioblastoma Multiforme | Recurrent Glioblastoma

Poland
NovoCure Ltd.

Unknown

TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBM

Glioblastoma Multiforme

Israel
NovoCure Ltd.

Completed

Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)

Malignant Pleural Mesothelioma

Netherlands, Italy, Germany, Belgium, France, Poland, Spain
NovoCure Ltd.

Unknown

Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)

1-5 Brain Metastases From Non-Small Cell Lung Cancer

Poland, Czech Republic, Italy, France, Spain
NovoCure Ltd.

Recruiting

Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM

Glioblastoma Multiforme

Czechia
NovoCure Ltd.

Completed

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

Ovarian Cancer

United States, Israel, Belgium, Netherlands, Hungary, Germany, Poland, Canada, Austria, Czechia, Italy, Spain, Switzerland
NovoCure Ltd.

Active, not recruiting

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

Pancreas Adenocarcinoma

United States, China, Belgium, Czechia, Korea, Republic of, Spain, Hong Kong, France, Australia, Italy, Hungary, Germany, Croatia, Canada, Mexico, Israel, Austria, Switzerland, Brazil, Poland
NovoCure Ltd.

Unknown

TTFields In GErmany in Routine Clinical Care (TIGER)

Glioblastoma

Germany
NovoCure Ltd.

Unknown

Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)

Pancreatic Adenocarcinoma

Spain, Switzerland
NovoCure Ltd.

Completed

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States, Spain, France, Canada, Korea, Republic of, Austria, Israel, Czech Republic, Germany, Italy, Sweden, Switzerland
NovoCure Ltd.

Terminated

Post-approval Study of NovoTTF-100A in Recurrent GBM Patients

Recurrent Glioblastoma Multiforme

United States
NovoCure Ltd.

Completed

NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

Switzerland
NovoCure Ltd.

Recruiting

TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning Study

Glioblastoma

Germany
NovoCure Ltd.

Unknown

Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)

Ovarian Carcinoma

Switzerland, Belgium, Germany, Spain
NovoCure Ltd.

Completed

Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)

Recurrent Glioblastoma Multiforme

United States, Israel, Switzerland, Austria, Czech Republic, France, Germany
Duke University
NovoCure Ltd.

Completed

Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields (ACTION)

Malignant Glioma

United States
Mayo Clinic
NovoCure Ltd.

Recruiting

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

Pancreatic Adenocarcinoma | Pancreas Cancer | Metastatic Pancreatic Cancer | Metastatic Adenocarcinoma

United States
Stanford University
NovoCure Ltd.

Recruiting

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

Glioblastoma | Newly Diagnosed Glioblastoma

United States
Ashish Manne
Ohio State University; NovoCure GmbH

Recruiting

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma | Resectable Pancreatic Cancer

United States
Brown University
NovoCure Ltd.

Not yet recruiting

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Metastatic Melanoma | Melanoma Brain Metastasis

United States
AIO-Studien-gGmbH
Servier Deutschland GmbH; Crolll Gmbh

Active, not recruiting

2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy (PREDICT)

Metastatic Pancreatic Cancer | Locally Advanced Pancreatic Cancer

Germany
University of Florida
NovoCure Ltd.

Terminated

FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma (FORWARD)

Astrocytoma, Grade III | Astrocytoma, Grade II

United States
RTOG Foundation, Inc.
NovoCure Ltd.

Terminated

Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

Glioma | Glioblastoma | Gliosarcoma

United States
VisionHealth GmbH
Thoraxklinik-Heidelberg gGmbH

Recruiting

Effects of the Kata® Inhalations-App on Inhaler Handling Errors, Adherence, and Asthma Control in Patients With Asthma.

Asthma

Germany
Hackensack Meridian Health
NovoCure Ltd.

Active, not recruiting

HUMC 1612: Optune NovoTTF-200A System

High Grade Glioma | Ependymoma

United States
Institut Claudius Regaud
NovoCure Ltd.

Not yet recruiting

Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma (EXOFIELDS)

Glioblastoma

France
HonorHealth Research Institute
NovoCure Ltd.

Recruiting

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

Uveal Melanoma

United States
Wayne State University
NovoCure Ltd.

Completed

Tryptophan Metabolism in Human Brain Tumors

Glioblastoma

United States
University of Florida
NovoCure Ltd.

Active, not recruiting

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) (2-THE-TOP)

Glioblastoma | Glioblastoma, WHO Grade IV

United States
Hackensack Meridian Health
NovoCure Ltd.

Completed

NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Glioblastoma, Adult

United States
University of Florida
NovoCure Ltd.

Terminated

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

Glioblastoma | Glioblastoma Multiforme | Malignant Glioma | GBM

United States
AIO-Studien-gGmbH
Pfizer; Crolll Gmbh

Recruiting

Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy (PREPARE)

Renal Cell Carcinoma, Metastatic | Renal Cell Cancer, Recurrent

Germany
AIO-Studien-gGmbH
Celgene; ClinAssess GmbH

Completed

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer (NEONAX)

Resectable Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

Germany
Thoraxklinik-Heidelberg gGmbH
Erbe Elektromedizin GmbH

Completed

EBUS Guided Cryobiopsies With Ultrathin Cryoprobe in Patients With Peripheral Pulmonary Nodules - a Feasibility Study

Transbronchial Cryobiopsy

Germany
AIO-Studien-gGmbH
Sanofi; ClinAssess GmbH

Terminated

A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet) (CaBaMet)

Breast Cancer | Lung Cancer | Recurrent Brain Metastases | Progressive Brain Metastases

Germany
AIO-Studien-gGmbH
Amgen; ClinAssess GmbH

Completed

FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI) (VOLFI)

Metastatic Colorectal Cancer

Germany
AIO-Studien-gGmbH
Amgen; ClinAssess GmbH

Completed

Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer (PanaMa)

Metastatic Colorectal Cancer

Germany
Saint Luke's Health System
NovoCure Ltd.

Withdrawn

Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS Lymphoma

Central Nervous System Neoplasms, Primary
University of Maryland, Baltimore
NovoCure Ltd.

Terminated

Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)

Brain Tumor | RECURRENT GLIOBLASTOMA

United States
University of Maryland, Baltimore
NovoCure Ltd.

Unknown

Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal Tissues

Esophageal Cancer | Lung Cancer | Mesothelioma; Lung

3

Subscribe